Considerations for the safe prescribing and use of COX-2-specific inhibitors

David R. Barraclough, James V. Bertouch, Peter Brooks, Mark A. Brown, Leslie G. Cleland, Laurie E. Clemens, Steven J. Crowley, Richard O. Day, Julien P. DeJager, John P. Edmonds, Peter J. Fletcher, Gary R. Franks, David C. Harris, John D. Horowitz, Michael D. Johnston, Stephen J. Kerr, Geoff O. Littlejohn, Graham J. MacDonald, Geoff J. McColl, Phillip N. SambrookSepehr Shakib, Murray W. Verso, Neville D. Yeomans

Research output: Contribution to journalReview ArticleResearchpeer-review

21 Citations (Scopus)

Abstract

The majority of the "Australian COX-2-Specific Inhibitor (CSI) Prescribing Group" endorse the following points: ■ CSIs are equivalent to non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory agents. ■ CSIs and NSAIDs modify symptoms but do not alter the course of musculoskeletal disease. ■ CSIs do not eliminate the occurrence of ulcers or their serious complications, but are associated with considerably fewer peptic ulcers, slightly fewer upper GI symptoms and, according to published reports, fewer serious upper GI complications, notably bleeding, than NSAIDs. ■ CSIs and NSAIDs have similar effects on renal function and blood pressure. ■ Whether any CSI poses a risk to cardiovascular safety remains subject to debate. ■ Comorbidities and coprescribed drugs must be considered before initiating CSI (or NSAID) therapy. ■ Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy.

Original languageEnglish
Pages (from-to)328-331
Number of pages4
JournalMedical Journal of Australia
Volume176
Issue number7
Publication statusPublished - 1 Apr 2002

Cite this